Literature DB >> 1692602

Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness?

R M Douglas1, B Moore, H B Miles, C B Pinnock.   

Abstract

Recent studies have demonstrated that rhinovirus infections can be prevented in the family setting through use of intranasal interferon sprays which are commenced when another family member develops a cold. One hundred and twenty-seven children aged 4-9 years who had been hospitalized during their first year of life for severe infections caused by respiratory syncytial virus were studied virologically and epidemiologically during a seven-month period which included the winter months. The hypothesis was that a significant part of their respiratory morbidity would be preventable by a contact prophylaxis approach using intranasal interferon. However, the findings suggest that a preventive approach of this kind would not substantially reduce the burden of respiratory illness in these children because: the target children themselves more often introduced illness into the family than did other household members; rhinovirus infections preventable by interferon were associated with little lower respiratory morbidity; and rhinoviruses were minor contributors to the total respiratory illness burden in these respiratory illness-prone children.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692602      PMCID: PMC7168430          DOI: 10.5694/j.1326-5377.1990.tb125353.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.

Authors:  F G Hayden; J K Albrecht; D L Kaiser; J M Gwaltney
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

2.  Vitamin A status of children with a history of respiratory syncytial virus infection in infancy.

Authors:  C B Pinnock; R M Douglas; A J Martin; N R Badcock
Journal:  Aust Paediatr J       Date:  1988-10

3.  Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting.

Authors:  R M Douglas; B W Moore; H B Miles; L M Davies; N M Graham; P Ryan; D A Worswick; J K Albrecht
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

4.  Outcome for acute bronchitis, bronchiolitis, and pneumonia in infancy.

Authors:  J Y Mok; H Simpson
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

5.  Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection.

Authors:  R M Douglas; J K Albrecht; H B Miles; B W Moore; R Read; D A Worswick; A J Woodward
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

  5 in total
  2 in total

Review 1.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

2.  A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.

Authors:  Lulu Gao; Shouyi Yu; Qing Chen; Zhaojun Duan; Jie Zhou; Chen Mao; Dexian Yu; Wenchang Zhu; Jun Nie; Yunde Hou
Journal:  Vaccine       Date:  2010-04-13       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.